Significant Ownership of Thomas A. Satterfield Jr.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Thomas A. Satterfield Jr. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager location
- Birmingham, AL
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
1 identity field
Follow Filing Activity
Follow Thomas A. Satterfield Jr. with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Thomas A. Satterfield Jr.
Significant Ownership of Thomas A. Satterfield Jr.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ARKR | Ark Restaurants Corp. | Common Stock, par value $0.01 per share | 17% | $5,675,303 | +$438,134 | 622,292 | +8.4% | Thomas A. Satterfield, Jr. | 05 Aug 2025 |
| CRIS | Curis, Inc. | Common Stock, par value $0.01 per share | 9.9% | $2,176,872 | +$1,607,203 | 3,957,950 | +282% | Thomas A. Satterfield, Jr. | 31 Mar 2026 |
| BCDA | BioCardia, Inc. | Common Stock, par value $0.001 per share | 9.9% | $1,356,010 | +$467,153 | 592,144 | +53% | Thomas A. Satterfield, Jr. | 30 Jun 2025 |
| SCND | Scientific Industries, Inc. | Common Stock, $.05 par value | 9.9% | $1,183,577 | 1,138,055 | Thomas A. Satterfield, Jr. | 31 Dec 2024 | ||
| OSTX | OS Therapies Incorporated | Common Stock, par value $0.001 per share | 9.4% | $5,296,658 | +$3,141,967 | 3,115,681 | +146% | Thomas A. Satterfield, Jr. | 30 Jun 2025 |
| NVNO | enVVeno Medical Corporation | Common Stock, $0.00001 par value per share | 9% | $1,348,650 | 1,822,500 | Thomas A. Satterfield, Jr. | 14 Nov 2025 | ||
| LTRN | Lantern Pharma Inc. | Common Stock, $0.0001 par value per share | 7.6% | $4,065,750 | +$1,688,850 | 975,000 | +71% | Thomas A. Satterfield, Jr. | 30 Jun 2026 |
| CTSO | CytoSorbents Corporation | Common Stock, par value $0.001 per share | 6.6% | $4,638,686 | 3,998,867 | Thomas A. Satterfield, Jr. | 13 Jan 2025 | ||
| ALCO | Alico, Inc. | Common Stock | 6.4% | $17,711,970 | 486,836 | Thomas A. Satterfield, Jr. | 31 Dec 2025 | ||
| CHRS | Coherus Oncology, Inc. | Common Stock, $0.0001 par value per share | 4.6% | $11,711,700 | +$1,555,621 | 6,930,000 | +15% | Thomas A. Satterfield, Jr. | 31 Mar 2026 |
| INTT | inTest Corporation | Common Stock, par value $0.01 per share | 4.4% | $7,507,500 | -$6,150,608 | 550,000 | -45% | Thomas A. Satterfield, Jr. | 31 Mar 2026 |
| EDSA | Edesa Biotech, Inc. | Common Stock, without par value | 0% | $0 | -$547,900 | 0 | -100% | Thomas A. Satterfield, Jr. | 13 Feb 2025 |
Schedules 13D/G Reported by Thomas A. Satterfield Jr.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.